

Pain Therapeutics

Drugs, Markets & Companies

By

Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

April 2018

A Jain PharmaBiotech Report

A U T H O R ' S B I O G R A P H Y

Professor K. K. Jain is a neurologist/neurosurgeon by training and received graduate training in both Europe and US. He has held academic positions in several countries and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. During his active neurosurgical career, Prof. Jain was involved in the management of pain. He has been working in the biotechnology/biopharmaceuticals industry for several years and currently is the CEO at Jain PharmaBiotech.

Prof. Jain is an Associate Editor of MedLink Neurology, an electronic encyclopedia of neurology published by Medlink Corporation (San Diego, California) where he is also the author in charge of writing and yearly update of 161 articles including those on treatment of pain.

Prof. Jain's 476 publications include 30 books (6 as editor + 24 as author) and 50 special reports which have covered important areas in biotechnology, gene therapy and biopharmaceuticals. He has also written a textbook of gene therapy, which is the first book on this subject to be translated into the Chinese language. A book on gene therapy companies was published in 2000 by John Wiley & Sons and the updated version has been incorporated into a report on Gene Therapy published by Jain PharmaBiotech in 2014. Prof. Jain has edited "Drug Delivery Systems" (Humana/Springer 2008, 2nd ed 2014) and "Drug Delivery to the Central Nervous System" (Humana/Springer 2010). His other recent books include "Handbook of Nanomedicine" (Springer/Humana 2008; Chinese edition, Peking University Press 2011, 2nd ed Springer 2012, 3rd ed 2017), "Textbook of Personalized Medicine" (Springer 2009; Japanese ed 2012; 2nd ed Springer, 2015), "Handbook of Biomarkers" (Springer 2010; Chinese edition, Chemical Industry Press 2016, 2nd ed Springer, 2017), "Handbook of Neuroprotection" (Springer 2011, 2nd edn 2018, in preparation), "Applications of Biotechnology in Cardiovascular Therapeutics" (Springer 2011), "Applications of Biotechnology in Neurology" (Springer 2013), and "Applications of Biotechnology in Oncology" (Springer 2014). He has edited "Applied Neurogenomics" (Springer 2015).

The pain report is an update with inclusion of commercial information in an earlier publication titled "Pain Therapeutics: A strategic re-evaluation" published by Reuter's Business Insight/Datamonitor UK in 2000. Other reports written by Prof. Jain in the past have been published by PJB Publications, D & MD, Informa, and Decision Resources Inc. This is one of the in-house publications of Jain PharmaBiotech that are constantly updated.

April 2018
Copyright ©2018 by

Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland

Tel & Fax: +4161-6924461
Email: info@pharmabiotech.ch
Web site: http://pharmabiotech.ch/

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

TABLE OF CONTENTS

0. Executive Summary	19
1. Basic Aspects of Pain	21
Introduction	21
Historical aspects of pain	21
Pain definitions	23
A glossary of terms relevant to pain	24
Pain classification and description	24
Neuropathic pain	25
<i>Refractory neuropathic pain</i>	26
<i>Classification of neuropathic pain according to levels</i>	26
Cancer pain	27
<i>Bone pain in cancer</i>	29
Complex regional pain syndrome	30
Mechanisms of pain	30
Pain pathways	31
<i>Role of nociceptors in pain transmission</i>	32
Gate control and neuromatrix theories of pain	32
Pain mediators	33
Modulation of pain by pictures associated with social contacts	34
Modulation of pain by emotions	34
Role of the sympathetic nervous system in pain	34
Visceral pain	35
<i>Pathomechanism of visceral pain</i>	35
Pathomechanism of neuropathic pain	35
<i>Role of intact nerve fibers in neuropathic pain</i>	35
<i>Chemokines as mediators of neuropathic pain</i>	36
<i>Chemotherapy-induced neuropathic pain</i>	36
<i>CNS innate immunity and neuropathic pain</i>	36
<i>Cytokines as mediators of neuropathic pain</i>	37
<i>Free radicals in generation of neuropathic pain</i>	37
<i>GABA deficiency in neuropathic pain</i>	37
<i>Genetic basis of neuropathic pain</i>	37
<i>Gene expression changes in neuropathic pain</i>	38
<i>Glial activation and neuropathic pain</i>	38
<i>Immune cell-derived opioids and neuropathic pain</i>	39
<i>Spinal leptin and neuropathic pain</i>	39
<i>Tetrahydrobiopterin regulates neuropathic pain sensitivity</i>	39
Pathomechanism of migraine	40
Role of the immune system in pain	41
Pain and itch	41
<i>Pathomechanism of itch</i>	41
<i>Clinical aspects of itch</i>	42
Molecular pathophysiology of pain	42
Role of ion channels in pain	43
<i>Acid-sensing ion channels</i>	43
<i>Calcium channels in pain</i>	43
<i>P2X3 ion channels</i>	44
<i>Potassium ion channels</i>	44
<i>Sodium ion channels in pain</i>	45
<i>TRP ion channels in pain</i>	46
Genetic basis of pain	47
<i>Alternative RNA splicing and pain</i>	47
<i>Study of genes in pain</i>	48
<i>Pain as a channelopathy</i>	48
Pain in the brain	49
<i>Effect of chronic pain on opioid receptors in the brain</i>	49
<i>Neuropathic pain-induced morphological changes in the brain</i>	49
Change from acute to chronic pain	50
<i>Acute versus chronic pain</i>	50
<i>Descending facilitatory modulation of pain</i>	50
<i>Development of chronic pain following severe accidental injury</i>	51
<i>Pain and transcriptional repressor DREAM</i>	51
<i>Role of neuronal plasticity in pain</i>	51
<i>Role of epigenetics in development of chronic pain</i>	52
<i>Concluding remarks on evolution of acute pain into chronic pain</i>	52
Neurochemistry of pain	52
<i>Molecular elements of pain in the peripheral nervous system</i>	52

<i>Molecular elements of pain in the central nervous system</i>	53
<i>Opioid receptors</i>	54
<i>Role of AMPA receptors in chronic pain</i>	54
<i>Kinins</i>	54
<i>Serotonin</i>	55
<i>Substance P</i>	55
<i>Excitatory amino acids</i>	56
<i>Role of nitric oxide in pain</i>	56
<i>Prostaglandins</i>	56
<i>Endocannabinoids</i>	58
<i>Protein kinase C</i>	58
<i>Adenosine and adenosine receptors</i>	58
<i>Vitamin D and pain</i>	59
<i>Vanilloid receptor</i>	59
<i>TRPA₁ and TRPV₁ receptors</i>	59
<i>Endothelin-B receptors</i>	61
<i>Nerve growth factor and pain</i>	61
<i>Adrenomedullin as a pain-related peptide</i>	61
Biomarkers of pain	62
<i>Biomarkers of visceral pain</i>	62
2. Assessment of Pain and Analgesics	64
Introduction	64
Animal models of pain	64
An overview	64
Selection of animal species as models for pain	64
Types of noxious stimuli	65
Animal models of neuropathic pain	65
Animal models of arthritis	65
Animal models of peripheral neuropathy	66
Limitations of current pain models	66
NeuroDigm GEL Model™ of neuropathic pain	67
Ethical issues concerning animal pain models	67
Medical evaluation of pain	68
Chronic pain as a manifestation of various diseases	68
Assessment of pain patients	68
Medical examination	68
Measurement of pain	69
Quality of pain intensity assessment in clinical research studies	70
Quantitative sensory testing	71
Pain measurement tools for neonates and children	71
Quantitative sensory testing	72
Microneurographic recordings	72
Psychological assessment of pain	73
Testing for in vivo pain processing	73
Brain imaging in pain	73
<i>fMRI for study of pain</i>	73
<i>PET for study of pain</i>	73
<i>PET correlated with fMRI and evoked potentials</i>	74
Patient outcomes and quality of life during treatment for chronic pain	74
Collection and analysis of data on pain patients	75
Evaluation of analgesics in humans	75
Early phase clinical trials of analgesics in humans	75
Design of clinical trials for pain	76
Assessment of neuropathic pain	77
Transdermal electrical stimulation for study of chronic pain	77
Placebo effect in pain	78
Role of electronic pain recording in determination of the placebo effect	78
Outcome measures for chronic pain trials	78
Pain, pain therapies and cognitive function	79
3. Pharmacotherapy of Pain	80
Introduction	80
Mechanism of action of currently used pain medications	80
Non-steroidal antiinflammatory drugs	81
COX-2 inhibitors	81
<i>Celecoxib</i>	82
<i>Metamizole</i>	83
<i>Nimesulide</i>	83
<i>Rofecoxib</i>	83
<i>Valdecoxib</i>	84

<i>Lumiracoxib</i>	84
<i>Side effects of COX inhibitors</i>	84
<i>Innovative COX-2 inhibitors in development</i>	86
Acetaminophen.....	87
Antioxidants as analgesics.....	87
Opiates and opioids	87
Morphine	88
Codeine	88
Tramadol	89
Innovations in opioid therapy	89
<i>Oral transmucosal fentanyl</i>	90
<i>Use of opioids for chronic non-cancer pain</i>	90
Opioid receptor modulation for visceral pain	90
Opiorphin.....	91
N-methyl-D-aspartate receptor antagonists	91
Ketamine	91
CNS 5161	92
Triptans for treatment of non-migrainous pain.....	92
Capsaicin	92
NGX-4010.....	93
Local anesthetics	93
Topical application	93
Nerve blocks	93
<i>Injection of local anesthetics for analgesia</i>	94
<i>Ultrasound-guided nerve blocks</i>	94
Topical salicylates for the treatment of pain.....	94
Topical rubefacients for acute and chronic pain in adults	94
Adjunctive analgesics	95
Antidepressants.....	95
<i>Mechanism of analgesic action of antidepressants</i>	96
Antiepileptic drugs	97
<i>Mechanism of action of antiepileptic drugs in neuropathic pain</i>	98
<i>Carbamazepine</i>	98
<i>Gabapentin</i>	99
<i>Lamotrigine</i>	99
<i>Phenytoin</i>	100
<i>Pregabalin</i>	100
<i>Topiramate</i>	101
<i>Valproic acid</i>	101
<i>Other antiepileptic drugs</i>	101
Clonidine.....	102
Baclofen.....	102
Corticosteroids	102
Calcitonin.....	103
Bisphosphonates	103
Botulinum toxins	103
Analgesic effect of botulinum toxin A.....	104
Engineered botulinum toxin.....	104
Analgesics from traditional medical systems	105
Herbs and other plants	105
Analgesics derived from cobra toxin	106

4. Management of Pain	108
Introduction	108
Sites for pain management.....	108
Self-medication at home	108
Physicians' offices	108
Major hospitals	108
Pain centers	109
Non-pharmacological approaches to pain	109
Alternative medicine.....	109
<i>Acupuncture</i>	110
<i>Aromatherapy</i>	110
<i>Self-Controlled Energo Neuro Adaptive Regulation</i>	111
Behavioral therapy.....	111
<i>Cognition and pain</i>	111
<i>Control over brain activation and pain by using functional MRI</i>	111
<i>Mindfulness meditation for relief of chronic pain</i>	112
<i>Thermal-grill illusion</i>	112
<i>Virtual reality therapy</i>	112
Local application of heat	112

Transcutaneous nerve stimulation.....	113
Non-invasive brain stimulation techniques for chronic pain.....	113
<i>Transcranial magnetic stimulation</i>	113
<i>Cranial electrotherapy stimulation</i>	114
Neurosurgery for pain relief.....	114
<i>Ablative procedures on the nervous system</i>	114
<i>Procedures on peripheral, spinal and cranial nerves</i>	114
<i>Vagal nerve stimulation for control of pain</i>	115
<i>Neuromodulation</i>	115
<i>Spinal cord stimulation</i>	116
<i>Brain stimulation</i>	117
<i>Implantation of drug delivery devices</i>	118
Management of special types of pain.....	118
Acute pain.....	118
<i>Management of acute renal colic: NSAIDs vs. opioids</i>	118
<i>Combination of opioids and NSAIDs for acute pain</i>	119
<i>Reasons for inadequate management of acute pain</i>	119
Perioperative pain management.....	119
<i>Devices for delivery of analgesics in the postoperative period</i>	120
<i>Drug combination for perioperative pain</i>	121
<i>Gabapentin for reduction of postoperative pain</i>	121
<i>Ketamine for perioperative pain</i>	121
<i>Opioids for perioperative pain</i>	122
<i>Perioperative pain in neurosurgery</i>	122
<i>Prolonged duration local anesthesia</i>	123
<i>Concluding remarks on the management of postoperative pain</i>	123
Pain in the intensive care unit.....	124
Pain associated with sports and exercise.....	124
Pain associated with trauma.....	125
Chronic pain and sleep.....	125
Chronic abdominal pain.....	125
Functional somatic syndromes.....	126
Fibromyalgia syndrome.....	126
<i>Pathomechanism of FMS</i>	127
<i>Management of FMS</i>	127
<i>Non-pharmacological therapies for FMS</i>	127
<i>Pharmacotherapy of FMS</i>	128
<i>Concluding remarks on management of FMS</i>	129
Erythromelalgia.....	129
Irritable bowel syndrome.....	130
<i>Opioids for IBS</i>	131
<i>Pregabalin for IBS</i>	131
<i>Tricyclic antidepressants for IBS</i>	131
<i>Serotonin-modulating drugs for IBS</i>	131
Musculoskeletal pain.....	132
Myofascial pain syndrome.....	132
<i>Non-pharmacological methods of treatment of MPS</i>	132
<i>Pharmacotherapy of MPS</i>	133
Osteoarthritis.....	134
<i>Pain aggravates osteoarthritis by crosstalk between CNS and the joint</i>	135
<i>Management of osteoarthritis</i>	135
Rheumatoid arthritis.....	136
<i>Management of pain in rheumatoid arthritis</i>	137
<i>Disease modifying therapies in rheumatoid arthritis</i>	137
<i>Resurgence of interest in gold-based treatments for RA</i>	138
Backache and sciatica.....	139
<i>Lumbar disc disease and sciatica</i>	140
<i>Management of back pain with analgesics</i>	141
<i>Miscellaneous medical therapies for backache and sciatica</i>	142
Neck pain.....	142
Chronic pelvic pain.....	143
<i>Prostatitis</i>	143
Cancer pain.....	143
<i>Adjuvant drugs for cancer pain</i>	144
<i>Alternative non-pharmacological methods</i>	144
<i>Anesthetic techniques</i>	145
<i>Management of bone pain in cancer</i>	145
<i>Non-opioid analgesics for cancer pain</i>	145
<i>Opioid treatment of cancer pain</i>	145
<i>Opioid breakthrough pains</i>	147
<i>Opioid-induced enhancement of cancer growth and its prevention</i>	147

<i>Opioids delivery methods for cancer pain</i>	147
<i>Opioid administration through implanted drug delivery devices</i>	148
<i>Radiation therapy</i>	148
<i>Surgical methods of cancer pain relief</i>	149
<i>Conclusions regarding management of cancer pain</i>	149
Chronic non-malignant pain	149
Headache	150
<i>Cluster headache</i>	151
<i>Chronic daily headache</i>	151
<i>Indomethacin-responsive headache</i>	152
<i>Occipital neuralgia</i>	152
<i>Paroxysmal hemicrania</i>	153
<i>Tension headache</i>	153
Migraine	153
<i>Management of acute migraine</i>	154
<i>Chronic migraine</i>	157
<i>Pediatric migraine</i>	158
<i>Status migrainosus</i>	158
<i>Migraine prophylaxis</i>	159
<i>Non-pharmacological approaches to migraine</i>	160
Trigeminal neuralgia	161
Dental pain	162
Neuropathic pain	162
<i>Pathogenesis of neuropathic pain</i>	162
<i>Chronobiology of neuropathic pain as guide to therapy</i>	163
<i>Management of neuropathic pain based on mechanism</i>	163
<i>Guidelines for the management of neuropathic pain</i>	164
<i>Pharmacotherapy of neuropathic pain</i>	164
<i>Evidence-based management of neuropathic pain</i>	166
Management of central neuropathic pain	167
<i>Neurosurgical approaches to central neuropathic pain</i>	167
<i>Management of neuropathic pain in syringomyelia</i>	168
<i>Neuropathic pain associated with spinal cord injury</i>	168
Management of peripheral neuropathic pain	168
<i>Truncal neuropathic pain</i>	169
<i>Management of postsurgical peripheral neuropathic pain</i>	169
<i>Management of chemotherapy-induced pain</i>	169
<i>Morton's neuroma</i>	170
<i>Management of peripheral diabetic neuropathy</i>	170
<i>Postherpetic neuralgia</i>	172
<i>Treatment of complex regional pain syndrome</i>	174
<i>An algorithm for the management of peripheral neuropathic pain</i>	175
Phantom limb pain	176
<i>Pathomechanism of phantom limb pain</i>	176
<i>Management of phantom limb pain</i>	176
Painful neuromas following amputation	178
Pain and depression	179
<i>Neurochemical link between pain and depression</i>	179
<i>Management of chronic pain and depression</i>	180
Miscellaneous painful conditions	180
<i>Burning mouth syndrome</i>	180
<i>Chronic unstable angina</i>	181
<i>Mastalgia</i>	181
<i>Ophthalmic pain</i>	182
<i>Pain in Parkinson's disease</i>	182
Pain in sickle cell disease	182
Management of chronic unexplained pain	183
Management of itching	183
<i>Topical applications for itching</i>	184
<i>Systemic therapies for itching</i>	185
<i>Non-pharmacological therapies for itch</i>	185
Management of pain in special population groups	186
Racial and ethnic differences in pain management	186
Pain in neonates	186
Management of pain in children	186
<i>Misuse of codeine in children</i>	188
Management of pain in the elderly	188
Management of pain in women	189
<i>Reasons for increased pain perception in women</i>	189
<i>Chronic pelvic pain in women</i>	190
<i>Gender differences in response to analgesics</i>	190

<i>Considerations for pain management in women</i>	190
Management of pain in neurologically handicapped persons	191
Management of pain in the cognitively impaired elderly people	191
Management of pain in brain-damaged minimally conscious patients	192
Management of pain in the terminally ill	192
Problems in the management of pain	193
Inadequate pain management	193
Problems with use of opioids	193
<i>Guideline for use of opioids</i>	194
<i>Opioid regulations</i>	195
<i>Opioids alternatives</i>	195
Excessive prescription of gabapentinoids	196
<i>Problems with use of gabapentinoids</i>	196
Patterns of analgesic consumption in France vs other European countries	197
Suggestions for improvement of pain management by healthcare providers	197
<i>Management of neuropathic pain refractory to first line treatment</i>	199
<i>Multidisciplinary approaches to pain management</i>	199
<i>Pain as the fifth vital sign</i>	199
<i>Reassessment of management of chronic pain</i>	199
5. Drug Delivery for Pain	202
Introduction	202
Intra-articular injection for relief of joint pain	203
Delivery of analgesics to peripheral nerves	203
Controlled release drug delivery for pain	204
Accelerating the effect of subcutaneous morphine	204
Controlled drug delivery at site of pain	204
Oral extended release opioids	205
<i>Extended release oral morphine</i>	205
<i>Controlled release oxycodone</i>	205
<i>Extended release oxymorphone</i>	205
<i>Oral extended release tramadol</i>	206
Extended release gabapentin	206
Use of nanotechnology for drug delivery for pain	207
Non-injection methods of delivery of analgesics	207
Topical applications for pain	208
<i>Topical local anesthetics</i>	208
<i>Topical NSAIDs</i>	208
<i>Topical and transdermal diclofenac</i>	209
<i>Topical application for postoperative pain</i>	209
Needle-free drug delivery for pain	210
<i>Glide SDI® solid dose injector</i>	210
<i>SUMAVEL™ DosePro™ needle-less injection</i>	210
Transdermal drug delivery for pain	210
<i>Relief of pain associated with minor medical procedures</i>	210
<i>Transdermal fentanyl</i>	211
<i>Transdermal ketoprofen</i>	212
<i>Transdermal nitroglycerine as an adjuvant to opioids</i>	213
<i>Transdermal buprenorphine</i>	213
<i>Transdermal trans-capsaicin</i>	213
<i>Powder Injection Systems</i>	213
Intranasal delivery of analgesics	214
<i>Intranasal morphine</i>	214
<i>Intranasal morphine derivatives</i>	215
<i>Intranasal fentanyl</i>	216
<i>Intranasal buprenorphine</i>	216
<i>Intranasal ketamine</i>	216
<i>Intranasal ketorolac</i>	217
<i>Nasal formulations for migraine</i>	217
Oral spray formulations for migraine	217
Delivery of analgesics by inhalation	217
Buccal transmucosal and sublingual delivery of analgesics	218
<i>Application for cancer pain</i>	218
<i>Application for non-cancer pain</i>	219
Pumps for drug delivery in pain	219
<i>Patient controlled analgesia</i>	220
<i>Postoperative pain pumps</i>	220
<i>Chronogesic (sufentanil) Pain Therapy System</i>	221
<i>PatchPump</i>	222
Intrathecal delivery of analgesics	222
Anatomical & physiological aspects of intrathecal drug delivery	222

Pharmacokinetics of intrathecal drug delivery	224
Epidural drugs	224
<i>Pharmacokinetics of analgesic drugs following epidural injection</i>	224
<i>Epidural glucocorticoids</i>	225
<i>Epidural etanercept</i>	225
<i>Epidural morphine</i>	225
Intrathecal drugs	225
<i>Intrathecal adenosine</i>	227
<i>Intrathecal baclofen</i>	227
<i>Intrathecal fadolmidine</i>	227
<i>Intrathecal lidocaine</i>	228
<i>Intrathecal magnesium sulfate</i>	228
<i>Intrathecal midazolam</i>	228
<i>Intrathecal opioids</i>	228
<i>Intrathecal neostigmine</i>	229
<i>Intrathecal octeoride</i>	230
<i>Intrathecal non-NMDA antagonists</i>	230
<i>Intrathecal prostaglandin antagonists</i>	230
<i>Intrathecal resiniferatoxin</i>	230
<i>Intrathecal ziconotide</i>	231
Combinations of intrathecal agents for relief of pain	231
Pumps for intrathecal delivery of analgesics	232
Complications of intrathecal delivery of analgesics	232
Concluding remarks on intrathecal delivery of analgesic agents	233
Intracerebroventricular morphine for pain	233
Development of drug delivery systems for pain therapy	234
Delivery of analgesics to the CNS across the blood brain barrier	234
Drug delivery systems in clinical trials	234
6. Drug Development for Pain.....	238
Introduction	238
Drugs in development for pain.....	238
Current research goals	239
The ideal analgesic.....	239
Pain R & D goals in the pharmaceutical industry	239
Drug targets in the spinal cord	240
Drug targets in the brain	240
Molecular targets for analgesic drugs.....	240
Activation of P2X7 receptors.....	240
Alfa2-adrenergic receptor agonists	241
Angiotensin II type 2 receptor	241
Anti-NGF strategies	241
Bradykinin antagonists	241
Cannabinoids.....	242
<i>Cannabinoid receptor agonists</i>	242
<i>Cannabidiol</i>	244
<i>Cannabinor</i>	245
<i>Nabilone</i>	245
Capsaicin and VR1 receptor-based analgesics	246
<i>Vanilloid (capsaicin) receptor antagonists</i>	246
<i>VR1 receptor agonists</i>	246
CCR2 receptor blockade.....	247
Cholecystokinin antagonists	247
Cholinergic receptor agonists.....	247
Conotoxins as analgesics	248
Corticotropin-releasing factor	249
FAAH inhibitors.....	249
<i>PF-3845</i>	250
<i>URB597</i>	250
FKBP51 as a target for treatment of chronic pain	250
Free radical scavengers as analgesics	251
<i>Superoxide dismutase mimetics</i>	251
GABA analogs.....	251
<i>Subtype-selective GABAergic drugs</i>	251
Glutamate receptor antagonists	252
<i>NMDA receptor modulation for neuropathic pain</i>	252
<i>Alternatives to direct blocking of NMDA receptors</i>	252
<i>Glycine antagonists</i>	253
<i>Metabotropic glutamate receptors</i>	253
Histogranin-like compounds for the management of pain	253
Ion channels as targets for analgesic drugs	254

<i>Acid-sensing ion channels as drug target</i>	254
<i>Calcium channel blockers</i>	255
<i>HCN1 channels as targets for propofol analogs for neuropathic pain</i>	255
<i>P2X ion channel receptor antagonists</i>	256
<i>Sodium channel modulation</i>	256
Mas-related GPCR agonists	257
Microsomal prostaglandin E synthase inhibitors	257
NAALADase inhibitors	258
Neuropeptide receptor antagonists for improving the efficacy of opioids	258
Neurotrophic factor-based pain therapeutics	259
<i>Glial cell line-derived neurotrophic factor</i>	259
<i>Nerve growth factor antagonists</i>	259
Newer COX inhibitors	260
<i>COX-3 inhibitors</i>	260
<i>Dual cyclooxygenase/lipoxygenase inhibitors</i>	260
Nicotinic acetylcholine receptors	260
<i>Mode of action of nACh/neural nicotinic receptor agonists</i>	261
<i>Potential of central nACh/neural nicotinic receptor agonists</i>	261
Nitric oxide-based analgesics	262
<i>Nitric oxide-releasing NSAIDs</i>	262
<i>Pharmacology of NO-SAIDs</i>	263
<i>COX-inhibiting nitric oxide donors</i>	263
<i>NO-donating structures to extend life cycle of existing analgesics</i>	263
<i>Nitric oxide mimetics</i>	264
<i>Neuronal nitric oxide synthase inhibitors</i>	264
Norepinephrine transporter inhibition	264
Opioid peptide receptors ligands	265
<i>Buprenorphine</i>	266
<i>Nociceptin</i>	266
<i>Opioids with unique receptor characteristics</i>	266
<i>Tapentadol</i>	266
Opioid analgesics acting outside the CNS	267
<i>Oliceridine</i>	267
<i>Opioid analgesics acting at peripheral receptors</i>	268
<i>Peripherally acting mu-opioid receptor agonists</i>	268
<i>Targeting of opioid peptide-containing immune cells</i>	268
<i>Advantages of peripherally selective opioid drugs</i>	268
Resolvins	269
Somatostatin analogs	269
Substance P and neurokinin receptor antagonists	269
Substance P-Saporin	270
Targeting prostanoid synthesis	271
Tetrodotoxin based analgesics	271
TRPV1 modulators	272
<i>TRPV1 antagonists</i>	272
<i>TRPV1 agonists</i>	273
<i>TRPV1-mediated entry of sodium channel blocker QX-314</i>	273
<i>TRPV1 receptors regulate longevity</i>	274
Tumor necrosis factor- α antagonists	274
Biological therapies for pain	274
Cell therapy for pain	275
Cells for delivery of antinociceptive molecules	276
Cell therapy for low back pain	276
Cell therapy for knee pain due to degenerative disorders	276
Cell therapy for peripheral neuropathic pain	277
Cell transplantation for relief of pain	277
<i>Transplantation of chromaffin cells</i>	277
<i>Transplantation of stem cells</i>	278
<i>Transplantation of astrocytes secreting enkephalin</i>	278
<i>Transplantation of cells for relief of neuropathic pain</i>	278
Concluding remarks on cell therapy for pain	279
Gene therapy for pain	279
Rationale of gene therapy for pain	280
<i>Gene therapy of peripheral neuropathy</i>	280
<i>Gene therapy targeted to neuroimmune component of chronic pain</i>	281
Methods of gene delivery for pain	281
Vectors for gene therapy of pain	282
<i>Vectors for endogenous analgesic production in cranial neuralgias</i>	282
Methods of gene delivery for pain	282
<i>Gene delivery by intrathecal route</i>	282
<i>Gene transfer to the dorsal nerve roots</i>	283

Gene transfer by injections into the brain substance.....	284
Antisense therapy for pain	284
RNAi-based approaches for pain therapy.....	285
Potential applications of gene therapy for management of pain.....	286
Gene therapy for producing enkephalin to block pain signals	286
Gene therapy for upregulation of BMP in backache	287
Gene therapy for targeting nuclear factor- κ B.....	288
Gene therapy for neuropathic pain	288
Zinc finger DNA-binding protein therapeutic for chronic pain	288
Concluding remarks about gene therapy for pain	289
Preclinical development of pain drugs	290
NGF-blocking antibody.....	290
Prostatic acid phosphatase as a novel analgesic.....	290
Preclinical development of drugs for neuropathic pain.....	291
5-HT receptor agonists	292
A-803467.....	292
α 9a10 antagonists	292
AM1241	293
Artemin/Neuroblastin	293
Capsazepine.....	294
Central nACh receptor agonists.....	294
CGP 35024.....	294
Cortistatin	295
Drugs that suppress glial activation	295
Erythropoietin.....	296
NO donating GABA-agonist drugs.....	296
Resiniferatoxin.....	296
Targeting tumor necrosis factor	297
Future targets for osteoarthritic pain	297
Pain drugs in clinical trials.....	297
Clinical trials of miscellaneous drugs for pain	297
Alvimopan.....	299
Asimadoline	300
EN3202	300
Oxytrex	300
Drugs in clinical trials for postsurgical pain	301
Bicifadine.....	301
DepoMorphine	302
Cox-2 inhibitors in clinical trials	303
Clinical trials of disease modifying therapies for arthritis	303
Drugs in clinical development for neuropathic pain	305
Adenosine A1 agonists for neuropathic pain	307
Ajulemic acid.....	307
AVP-923 (dextromethorphan + quinidine).....	308
Botulinum toxin type A	308
Carisbamate.....	309
CNV1014802	309
D-amino acid oxidase inhibitors	309
Glyx-13	309
IP-751	309
Lacosamide.....	310
Oxcarbazepine.....	310
Perampanel.....	310
Ralfinamide.....	311
Retigabine.....	311
SB-509.....	311
TC-6499	311
Tebanicline.....	312
Tezampanel	312
Thalidomide	312
TRO19622.....	313
V3381 (indantadol)	313
XP-13512.....	313
Zonisamide	314
Drug discovery and development for migraine	314
Drugs in clinical development for treatment of migraine.....	314
Clinical development of preventive therapies for migraine	318
Monoclonal antibodies targeting CGRP for migraine prophylaxis	318
Drug development for visceral pain	319

7. Safety, Regulatory and Legal issues of pain management 322

Safety issues of analgesics	322
Adverse effects of analgesics.....	322
Gastrointestinal adverse effects of NSAIDs.....	322
<i>Measures to reduce gastrointestinal adverse effects of NSAIDs</i>	<i>322</i>
Cardiovascular adverse effects of COX-2 inhibitors.....	322
Adverse effects of opioids	323
<i>Addiction and development of tolerance.....</i>	<i>323</i>
<i>Chronic pain and opioid addiction.....</i>	<i>324</i>
<i>Abuse-deterrent opioid products</i>	<i>325</i>
<i>Problems and limitations of abuse-deterrent opioids.....</i>	<i>326</i>
<i>Complications of opioid abuse in the elderly</i>	<i>327</i>
<i>Hyperalgesia associated with opioids</i>	<i>327</i>
<i>Narcotic bowel syndrome</i>	<i>328</i>
<i>Opioid use disorder</i>	<i>328</i>
<i>Opioid withdrawal</i>	<i>329</i>
<i>Opioid-associated constipation.....</i>	<i>329</i>
<i>Respiratory depression</i>	<i>329</i>
Role of opioid prescribing patterns of physicians	329
Adverse effects of use of opioids in non-malignant pain	330
<i>Pharmacogenetics of adverse effects of codeine.....</i>	<i>330</i>
<i>PEGylated naloxol</i>	<i>331</i>
<i>Innovative approaches to modify opioid pharmacology</i>	<i>331</i>
Adverse effects of miscellaneous non-narcotic analgesics.....	331
<i>Adverse effects of immunosuppressants used for relief of pain.....</i>	<i>331</i>
<i>Adverse effects of acetaminophen.....</i>	<i>332</i>
<i>Hyponatremia as an adverse effect of tramadol</i>	<i>332</i>
Regulatory issues	332
Opioids.....	332
DEA and use of opioids for pain relief in terminal care	332
Cannabinoids.....	333
FDA and COX-2 inhibitors.....	333
Legal issues of COX-2 inhibitors	334
Regulatory aspects of opioid safety and abuse	334
Opioid misuse and regulatory agencies	334
FDA measures for safety of opioid use	335
Misuse of fentanyl.....	336
Regulation of extended release and long-acting opioids	336
Pain relief as a legal right.....	338
Pain relief and the WHO.....	338
8. Pain Markets.....	340
Introduction	340
Epidemiological basis of pain markets	340
Cancer.....	341
Neuropathic pain.....	341
Trigeminal neuralgia.....	341
Arthritis	341
Backache	341
Migraine	342
Multiple sclerosis.....	342
Irritable bowel syndrome	342
Chronic pelvic pain.....	342
Chronic pain due to traumatic brain injury	342
Postsurgical pain.....	343
Economics of pain	343
Pain as a driver of healthcare costs	343
Disability and financial loss through pain.....	344
Pain markets based on painful conditions.....	344
The cancer pain market	344
The arthritis pain market	345
Postsurgical pain market.....	345
The backache market	345
The headache market.....	346
Neuropathic pain market.....	346
Fibromyalgia market	347
Pain markets based on drugs.....	347
Opioids.....	347
Nonsteroidal antiinflammatory drugs	348
Transdermal pain therapeutics.....	348
Anesthesia	348
Antiepileptic drugs as analgesics	349

Other drugs.....	349
Hospital vs retail share of pain market.....	349
<i>Hospital versus retail opioid market</i>	349
Devices for pain.....	349
Pain markets according to geographical areas.....	350
Cost effectiveness of various approaches	350
Unfulfilled R&D needs in pain therapy	351
Under treatment of pain	351
Unfulfilled needs in drug development for chronic pain	351
Strategies for developing pain markets	352
Finding alternatives to intrathecal administration for chronic pain	352
Development of other applications of analgesic drugs.....	352
Partnership of patients, pharmacists and companies.....	353
Factors that may influence future pain markets	353
Drivers of pain markets	353
Public surveys as indicators of impact of pain on people.....	354
Effect of regulatory reviews on markets for pain products	354
Novel versus older therapies for pain.....	355
9. Future of Pain Therapeutics.....	356
Introduction	356
Advances in the understanding of pain	356
Pathogenesis of chronic pain	356
Role of glia in neuropathic pain.....	356
Molecular and neurobiological techniques.....	357
Improved understanding of cancer pain	358
Advances in drug discovery and development for pain	358
Novel targets for drug discovery for pain	358
<i>PTH2 receptor</i>	358
<i>Modulators of endogenous cannabinoids</i>	359
Application of new technologies to pain therapeutics	359
<i>Application of nanobiotechnology to pain therapeutics</i>	360
<i>Technologies for the manufacture of analgesics</i>	361
Future trends and needs in pain management.....	361
Pain management in future healthcare systems	362
Systems biology approach to pain	362
Personalized management of pain	363
Genetic factors in response to pain.....	364
Genetic mutations with loss of pain	365
Genetic mutations and painful conditions	365
Mechanism-specific management of pain	365
Pharmacogenomics and pharmacogenetics of pain	366
Personalized management of pain with commonly used analgesics.....	366
<i>Pharmacogenomics and pharmacogenetics of opioids</i>	366
<i>Pharmacogenetics of NSAIDs</i>	367
Preoperative testing to tailor postoperative analgesic requirements.....	368
Role of conditioned pain modulation in personalized management of pain	368
Signature of pain on brain imaging.....	368
Strategies for improving pain management.....	369
Research on pain in Europe	369
10. Companies Involved in Pain Therapeutics.....	372
Introduction	372
Profiles of companies.....	372
Collaborations.....	552
11. References.....	558

Tables

Table 1-1: Landmarks in the history of pain therapeutics.....	22
Table 1-2: Classification of pain	24
Table 1-3: Classification of neuropathic pain	26
Table 1-4: Classification of chronic cancer pain according to cause.....	28
Table 1-5: Percentage of patients with pain according to the type of cancer	29
Table 1-6: Key molecular elements of pain in the peripheral nervous system	53
Table 1-7: Key molecular elements of pain in the central nervous system	53
Table 2-1: IASP guidelines for the use of animals in pain studies	67
Table 2-2: Chronic pain as a manifestation of other diseases.....	68

Table 2-3: Recommendations for assessing patient satisfaction with pain management	74
Table 3-1: Classification of some currently used pain medications according to mechanism	80
Table 3-2: Drugs used for the treatment of pain	80
Table 3-3: Selective COX-2 inhibitors in clinical use for pain	82
Table 3-4: Antiepileptic drugs with analgesic effect	97
Table 4-1: Non-pharmacological approaches to management of pain	109
Table 4-2: Companies involved in neuromodulation therapy for pain	115
Table 4-3: Reasons for the inadequate management of acute pain	119
Table 4-4: Monoclonal antibodies as disease modifying therapies in rheumatoid arthritis	137
Table 4-5: Causes of chronic backache	140
Table 4-6: Management of chronic pelvic pain	143
Table 4-7: Management of pain in cancer	144
Table 4-8: Definitions of tolerance, physiological dependence, withdrawal and addiction	150
Table 4-9: A simplified classification of headache	150
Table 4-10: Various methods for the management of acute migraine	154
Table 4-11: Prophylaxis and management of chronic migraine	157
Table 4-12: Evidence-based level of choice of drugs for prophylaxis of migraine	159
Table 4-13: Management of neuropathic pain based on mechanism and diagnosis	164
Table 4-14: Management of central neuropathic pain	167
Table 4-15: Current management of peripheral diabetic neuropathy	170
Table 4-16: Treatment strategies for postherpetic neuralgia	172
Table 4-17: Management of complex regional pain syndrome	174
Table 4-18: Methods of treating phantom limb pain	176
Table 4-19: Treatment of chronic unexplained pain due to central sensitization	183
Table 4-20: Anti-itching therapies	183
Table 4-21: Suggested improvements in the management of pain	198
Table 5-1: A classification of drug delivery methods used in management of pain	202
Table 5-2: Selected marketed non-injection drug delivery systems for pain	207
Table 5-3: Approved drugs for spinal administration for pain	225
Table 5-4: Off-label intrathecal use of drugs for pain	226
Table 5-5: Experimental studies of intrathecal administration of drugs for analgesia	226
Table 5-6: Intrathecal drugs for pain in clinical trials	226
Table 5-7: Comparison of pharmacokinetics of lipophilic with hydrophilic opioids	228
Table 5-8: Delivery systems for pain (other than intrathecal) in clinical development	235
Table 6-1: Classification of drugs in development for pain	238
Table 6-2: Preclinical studies on cannabinoid (CB2) receptor agonists as analgesics	243
Table 6-3: Cannabinoid receptor agonists in clinical development as analgesics	244
Table 6-4: NO-related therapies for pain	262
Table 6-5: Major opioids receptors and their ligands	265
Table 6-6: Strategies to counteract pain at various levels at periphery and in the CNS	271
Table 6-7: Types of TRPV1 antagonists	272
Table 6-8: TRPV1 antagonists in clinical trials	273
Table 6-9: Biological therapies for pain	275
Table 6-10: Experimental gene therapy approaches for relief of pain	281
Table 6-11: Selected preclinical approaches to pain therapy	290
Table 6-12: Selected preclinical drugs for neuropathic pain	291
Table 6-13: Selected clinical trials of miscellaneous drugs for pain	298
Table 6-14: Selected clinical trials of drugs for postsurgical pain	301
Table 6-15: COX-2 inhibitors in clinical development	303
Table 6-16: Disease modifying drugs for arthritis in clinical trials	303
Table 6-17: Clinical trials of drugs for neuropathic pain	305
Table 6-18: Selected drugs in clinical development for migraine	315
Table 6-19: CGRP receptor antagonists in clinical development for acute migraine	316
Table 6-20: Clinical trials of anti-CGRP monoclonal antibodies for migraine prevention	319
Table 6-21: Therapeutic targets for treating visceral pain	320
Table 7-1: Abuse-deterrant opioid products	326
Table 7-2: Diagnostic criteria for an opioid-use disorder	328
Table 8-1: Market values for various painful conditions 2017-2027	344
Table 8-2: Changes in market shares of drugs for neuropathic pain 2017-2027	346
Table 8-3: Markets for pain according to therapies 2017-2027	347
Table 8-4: Distribution of value of pain therapeutics in major markets 2017-2027	350
Table 8-5: Distribution of value of opioids in major pain markets 2017-2027	350
Table 8-6: Distribution of value of NSAIDs in major pain markets 2017-2027	350
Table 8-7: Strategies for developing pain markets	352
Table 9-1: P450 isoforms in the metabolism of drugs used in the management of pain	366
Table 10-1: Top companies in pain therapeutics	372
Table 10-2: Product pipeline of Adolor Corporation	379
Table 10-3: Selected collaborations in the area of pain management	552

Figures

Figure 1-1: Afferent pain pathways	31
Figure 1-2: Evolution of the gate control theory	33
Figure 1-3: The body self-neurometric.....	33
Figure 1-4: Various ligands and receptors on the peripheral terminals of nociceptive nerve fibers	53
Figure 1-5: Prostaglandin biosynthesis pathway	58
Figure 2-1: Biopsychosocial factors that interact and modulate the experience of pain.....	69
Figure 2-2: Pain intensity scales	70
Figure 3-1: Pathway of metabolism of codein	89
Figure 4-1: The WHO step ladder for pain	146
Figure 4-2: An algorithm for the acute management of migraine	155
Figure 4-3: Neuroimmune activation events leading to sensitization of CNS	163
Figure 4-4: An algorithm for the management of peripheral neuropathic pain.....	175
Figure 4-5: Algorithm for management of patients with chronic pain and depression.....	180
Figure 5-1: Powder Injection Systems	214
Figure 5-2: Penetration of CSF into spinal cord	223
Figure 5-3: Disposition of opioids after intrathecal administration	224
Figure 6-1: Attributes of the ideal analgesic	239
Figure 6-2: Nerve targeting drug delivery system for gene therapy of pain	287
Figure 8-1: Unfulfilled needs in the treatment for chronic pain.....	351
Figure 9-1: Impact of new technologies on pain therapeutics	360
Figure 9-2: Essential components of personalized management of pain	363
Figure 9-3: Genetic and non-genetic factors affecting efficacy and side effects of opioids.....	367